Radius Health upgraded by BofA Securities with a new price target
$RDUS
Industrial Specialties
Consumer Discretionary
BofA Securities upgraded Radius Health from Underperform to Neutral and set a new price target of $8.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/2/2024 | $22.00 | Neutral | Goldman |
| 5/30/2024 | Sell → Neutral | Seaport Research Partners | |
| 2/28/2024 | $17.50 | Neutral → Sell | Seaport Research Partners |
| 12/14/2023 | Neutral | Seaport Research Partners | |
| 6/8/2022 | $8.00 | Underperform → Neutral | BofA Securities |
| 5/23/2022 | $7.00 | Mkt Perform | SVB Leerink |
| 12/10/2021 | $18.00 → $7.00 | Equal-Weight → Underweight | Morgan Stanley |
| 12/10/2021 | $33.00 → $12.00 | Buy → Neutral | Goldman Sachs |
Submission status for RADIUS HEALTH INC's drug TYMLOS (SUPPL-13) with active ingredient ABALOPARATIDE has changed to 'Approval' on 12/19/2022. Application Category: NDA, Application Number: 208743, Application Classification: Efficacy
Submission status for RADIUS HEALTH INC's drug TYMLOS (SUPPL-10) with active ingredient ABALOPARATIDE has changed to 'Approval' on 12/22/2021. Application Category: NDA, Application Number: 208743, Application Classification: Efficacy
Submission status for RADIUS HEALTH INC's drug TYMLOS (SUPPL-10) with active ingredient ABALOPARATIDE has changed to 'Tentative Approval' on 10/28/2021. Application Category: NDA, Application Number: 208743, Application Classification: Efficacy
8-K - RADIUS RECYCLING, INC. (0000912603) (Filer)
8-K - RADIUS RECYCLING, INC. (0000912603) (Filer)
SCHEDULE 13G/A - RADIUS RECYCLING, INC. (0000912603) (Subject)
Goldman initiated coverage of Radius Recycling with a rating of Neutral and set a new price target of $22.00
Seaport Research Partners upgraded Radius Recycling from Sell to Neutral
Seaport Research Partners downgraded Radius Recycling from Neutral to Sell and set a new price target of $17.50